All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 30 October 20263 min read

Privi Speciality Chemicals (PRIVISCL) Q2 FY27 Profit Jumps 42% as Margins Recover

The aroma chemicals maker delivered a sharp profit beat as operational efficiency and lower costs drove margins back to management's target range.

By Abhinav Swaroop, CFA, Chief Business Officer: Hexawealth · Created 30 October 2026

Privi Speciality Chemicals reported a 30% yearly profit rise in Q2 FY27, with a 42% sequential jump driven by a 310 basis point margin expansion. The company also declared an interim dividend of ₹5 per share.

Privi Speciality Chemicals entered the second quarter with a clear task: translate strong demand into better profitability after a margin dip. The aroma chemicals maker delivered, with profit growth far outpacing sales as operational discipline took hold.

The numbers show a business hitting its stride. Revenue of ₹760 crore rose 12% from a year ago and 14% from the prior quarter. Profit, however, surged 31% year-on-year and a striking 42% sequentially to ₹118 crore. The net profit margin expanded to 15.5%, up 310 basis points from last quarter and 220 from a year ago.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ2 FY26 678.7, Q3 FY26 604.6, Q4 FY26 721.5, Q1 FY27 666.2, Q2 FY27 760.0. Q2 FY26 90.2, Q3 FY26 74.8, Q4 FY26 94.1, Q1 FY27 82.8, Q2 FY27 118.005001k1.5k2kQ2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26: 678.7
  • Revenue (₹ Cr), Q3 FY26: 604.6
  • Revenue (₹ Cr), Q4 FY26: 721.5
  • Revenue (₹ Cr), Q1 FY27: 666.2
  • Revenue (₹ Cr), Q2 FY27: 760.0
  • Profit (₹ Cr), Q2 FY26: 90.2
  • Profit (₹ Cr), Q3 FY26: 74.8
  • Profit (₹ Cr), Q4 FY26: 94.1
  • Profit (₹ Cr), Q1 FY27: 82.8
  • Profit (₹ Cr), Q2 FY27: 118.0

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY26 678.7, Q3 FY26 604.6, Q4 FY26 721.5, Q1 FY27 666.2, Q2 FY27 760.005001,0001,5002,000Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26: 678.7
  • Revenue (₹ Cr), Q3 FY26: 604.6
  • Revenue (₹ Cr), Q4 FY26: 721.5
  • Revenue (₹ Cr), Q1 FY27: 666.2
  • Revenue (₹ Cr), Q2 FY27: 760.0

Profit (₹ Cr)

Profit (₹ Cr)Q2 FY26 90.2, Q3 FY26 74.8, Q4 FY26 94.1, Q1 FY27 82.8, Q2 FY27 118.0050100150200Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Profit (₹ Cr), Q2 FY26: 90.2
  • Profit (₹ Cr), Q3 FY26: 74.8
  • Profit (₹ Cr), Q4 FY26: 94.1
  • Profit (₹ Cr), Q1 FY27: 82.8
  • Profit (₹ Cr), Q2 FY27: 118.0

Net Profit Margin (%)

Net Profit Margin (%)Q2 FY26 13.3, Q3 FY26 12.4, Q4 FY26 13.0, Q1 FY27 12.4, Q2 FY27 15.50%5%10%15%20%Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Net Profit Margin (%), Q2 FY26: 13.3
  • Net Profit Margin (%), Q3 FY26: 12.4
  • Net Profit Margin (%), Q4 FY26: 13.0
  • Net Profit Margin (%), Q1 FY27: 12.4
  • Net Profit Margin (%), Q2 FY27: 15.5
MetricCurrentQ2 FY27PreviousQ1 FY27Same quarter LYQ2 FY26
Revenue (₹ Cr)
760.0YoY +12%
666.2
678.7
Profit (₹ Cr)
118.0YoY +31%
82.8
90.2
Net Profit Margin (%)
15.5YoY +17%
12.4
13.3

Why margins did the heavy lifting

The profit beat was powered by a sharp recovery in profitability. According to StockWatch, the consolidated EBITDA margin recovered to around 26.3%, up from 22.9% in Q1 and back near the over-25% level management guides for. Expense growth at 8.2% was nearly half the pace of revenue growth, showing strong operating leverage.

Lower finance costs and a rise in other income also helped. A report from Multibagg.ai notes quarterly finance cost fell to ₹16.9 crore from ₹21.5 crore a year ago. Other income rose sharply to ₹12.7 crore from just ₹0.1 crore in Q2 FY26, providing a further tailwind to the bottom line.

The growth path ahead

While margin delivery is ahead of plan, the company's medium-term revenue target requires acceleration. Management's '5K:1K' vision aims for ₹5,000 crore revenue and over ₹1,000 crore EBITDA within 3-4 years, implying a 20% annual growth rate. This quarter's 12% yearly growth, though solid, trails that pace.

Live Chart

· PRIVISCL

(BSE)

ISIN: INE959A01019

The bridge to that target is capacity. The Phase-1 expansion to 54,000 MT, initially targeted for September 2026, is now key for near-term volume growth. Phase-2, taking capacity to 66,000 MT by September 2027, is backed by ₹850-900 crore of planned capex. As noted by InvestorFeed, expansion projects are progressing and expected to be ready for commercial operations in the second half of 2028.

The company is also simplifying its structure. Shareholders approved a Scheme of Amalgamation on October 27, merging Privi Fine Sciences and Privi Biotechnologies into the parent to unlock operational synergies.

Key Points

  • Profit surged 42% quarter-on-quarter to ₹118 crore, significantly outpacing 14% revenue growth due to a sharp 310 basis point margin expansion.
  • Operational efficiency drove the margin recovery, with EBITDA returning to the guided >25% range, supported by lower finance costs.
  • The company declared a first interim dividend of ₹5 per share for FY27, with a record date of November 4, 2026.
  • While profitability is ahead of target, achieving the medium-term ₹5,000 crore revenue goal requires growth to accelerate from the current 12% yearly pace.
  • Execution of the delayed Phase-1 capacity ramp and the ongoing merger to simplify the corporate structure are the immediate milestones to watch.

Hexa Perspective

Privi's quarter confirms its ability to defend and expand margins in a stable demand environment. The net profit margin of 15.5% is now above its trailing twelve-month average of 13.4%, suggesting the efficiency gains are material.

The story now pivots to volume. With margins back at target, the focus shifts squarely to the capacity ramp. The delayed Phase-1 expansion must start contributing to topline growth soon for the company to close the gap to its ambitious 20% CAGR target. Investors are weighing strong current execution against the future capital expenditure needed to get there.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Frequently asked questions

What were Privi Speciality Chemicals' Q2 FY27 results?
Privi Speciality Chemicals reported Q2 FY27 revenue of ₹760 crore, a 12% increase year-on-year. Net profit was ₹118 crore, a rise of 30.8% from the same quarter last year. The company's net profit margin expanded to 15.5%.
Did Privi Speciality Chemicals' profit rise or fall in Q2 FY27?
Privi Speciality Chemicals' profit rose significantly in Q2 FY27. Consolidated net profit increased by 30.8% compared to Q2 FY26, reaching ₹118 crore. Sequentially, profit jumped by 42.4% from the previous quarter.
What is Privi Speciality Chemicals' revenue for Q2 FY27?
Privi Speciality Chemicals reported consolidated revenue from operations of ₹760 crore for the quarter ended September 2026 (Q2 FY27). This represents a 12% growth from the ₹678.7 crore reported in the same quarter of the previous fiscal year.
Why did Privi's net profit margin expand in Q2 FY27?
Privi's net profit margin expanded to 15.5% in Q2 FY27, up 310 basis points from last quarter, due to operational efficiency. StockWatch reported EBITDA margin recovered to ~26.3%. Lower finance costs and higher other income also contributed to the bottom-line improvement.
What is Privi's '5K:1K' vision?
Privi's '5K:1K' vision is a medium-term target to achieve ₹5,000 crore in revenue and over ₹1,000 crore in EBITDA within the next 3-4 years, as noted by InvestorFeed. This implies a revenue compound annual growth rate of around 20% from current levels.
What is the status of Privi's capacity expansion?
Privi's capacity expansion is in progress. Phase 1 aims to increase capacity from 48,000 to 54,000 MT, with reports indicating a delay to September 2026. Phase 2 will further raise capacity to 66,000 MT by September 2027, backed by ₹850-900 crore of planned capital expenditure.
Did Privi declare a dividend with the Q2 results?
Yes, Privi Speciality Chemicals' board declared a first interim dividend of ₹5 per equity share for FY27. The record date for determining shareholder eligibility is November 4, 2026, with payment expected by November 25, 2026.
What is the update on Privi's merger plans?
Privi's shareholders approved the Scheme of Amalgamation on October 27, 2026. The scheme involves merging Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited into Privi Speciality Chemicals Limited to simplify the group structure and unlock synergies.
How has Privi's debt position changed?
Privi has demonstrated improved financial health. According to a report by Scanx.trade, the company's Net Debt to EBITDA ratio improved by 32.1% year-on-year to 1.07x as of September 30, 2026, indicating stronger balance sheet leverage.
What are the key risks for Privi Speciality Chemicals?
Key risks include execution of the delayed capacity expansion, volatility in raw material prices (like alpha-pinene), and the need to accelerate revenue growth to meet medium-term targets. Geopolitical and logistics disruptions also remain external risks, though the company has managed them well so far.